Heron Therapeutics (HRTX) Notes Payables (2011 - 2025)

Heron Therapeutics (HRTX) reported Notes Payables of $149.8 million for Q2 2025, up 1882.87% quarter-over-quarter from $7.6 million in Q1 2021.

Heron Therapeutics (HRTX) Notes Payables (2011 - 2025) Analysis & Trends

Heron Therapeutics has reported Notes Payables for 12 years, with the latest figure at $149.8 million in Q2 2025.

For the quarter ending Q2 2025, Notes Payables changed N/A year-over-year to $149.8 million; the trailing twelve-month figure through Jun 2025 stood at $149.8 million (changed N/A YoY), and the FY2020 full-year result was $7.1 million, up 25.41% from the prior year.
Notes Payables for Q2 2025 stood at $149.8 million, up from $7.6 million in the prior quarter.
The five-year high for Notes Payables was $149.8 million in Q2 2025, with the low at $7.6 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Heron Therapeutics	85.57 Mn	55.60 Mn	24.07 Mn

Download Data